Jurczak, W., Elmusharaf, N., Fox, C. P., Townsend, W., Paulovich, A. G., Whiteaker, J. R., . . . Munir, T. (2023). Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia. SAGE Publishing.
Chicago Style (17th ed.) CitationJurczak, Wojciech, et al. Phase I/II Results of Ceralasertib as Monotherapy or in Combination with Acalabrutinib in High-risk Relapsed/refractory Chronic Lymphocytic Leukemia. SAGE Publishing, 2023.
MLA (9th ed.) CitationJurczak, Wojciech, et al. Phase I/II Results of Ceralasertib as Monotherapy or in Combination with Acalabrutinib in High-risk Relapsed/refractory Chronic Lymphocytic Leukemia. SAGE Publishing, 2023.
Warning: These citations may not always be 100% accurate.